JP2016516726A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016516726A5 JP2016516726A5 JP2016503307A JP2016503307A JP2016516726A5 JP 2016516726 A5 JP2016516726 A5 JP 2016516726A5 JP 2016503307 A JP2016503307 A JP 2016503307A JP 2016503307 A JP2016503307 A JP 2016503307A JP 2016516726 A5 JP2016516726 A5 JP 2016516726A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- positions
- angptl4 polypeptide
- homology
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101710043760 ANGPTL4 Proteins 0.000 claims 11
- 229920001184 polypeptide Polymers 0.000 claims 11
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 6
- 108009000551 Nephrotic syndrome Proteins 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 206010012601 Diabetes mellitus Diseases 0.000 claims 4
- 201000001474 proteinuria Diseases 0.000 claims 4
- 102000015636 Oligopeptides Human genes 0.000 claims 3
- 108010038807 Oligopeptides Proteins 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229920000023 polynucleotide Polymers 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 208000007342 Diabetic Nephropathy Diseases 0.000 claims 2
- 206010061835 Diabetic nephropathy Diseases 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 206010018370 Glomerulonephritis membranoproliferative Diseases 0.000 claims 2
- 206010018372 Glomerulonephritis membranous Diseases 0.000 claims 2
- 208000009576 Hypercholesterolemia Diseases 0.000 claims 2
- 206010062060 Hyperlipidaemia Diseases 0.000 claims 2
- 208000002762 Hypoproteinemia Diseases 0.000 claims 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims 2
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 claims 2
- 206010030113 Oedema Diseases 0.000 claims 2
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims 2
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims 2
- 231100000852 glomerular disease Toxicity 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims 2
- 231100000855 membranous nephropathy Toxicity 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 235000003869 genetically modified organisms (GMOs) Nutrition 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000037317 transdermal delivery Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/841,240 | 2013-03-15 | ||
| US13/841,240 US9139629B2 (en) | 2010-06-05 | 2013-03-15 | Methods for treatment of nephrotic syndrome and related conditions |
| PCT/US2014/030009 WO2014145275A1 (en) | 2013-03-15 | 2014-03-15 | Methods for treatment of nephrotic syndrome and related conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016516726A JP2016516726A (ja) | 2016-06-09 |
| JP2016516726A5 true JP2016516726A5 (el) | 2017-04-20 |
Family
ID=51537930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016503307A Pending JP2016516726A (ja) | 2013-03-15 | 2014-03-15 | ネフローゼ症候群及び関連状態の治療方法 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP2970416B1 (el) |
| JP (1) | JP2016516726A (el) |
| KR (1) | KR102221041B1 (el) |
| CN (1) | CN105229024A (el) |
| AU (1) | AU2014233219B2 (el) |
| CA (3) | CA2906982C (el) |
| HK (1) | HK1220213A1 (el) |
| NZ (1) | NZ712935A (el) |
| WO (1) | WO2014145275A1 (el) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018006823A (es) * | 2015-12-21 | 2018-11-29 | Brainon Inc | Una composicion para mejorar la memoria, capacidad de aprendizaje y capacidad cognitiva. |
| KR101706296B1 (ko) | 2015-12-21 | 2017-02-13 | 주식회사 브레인온 | 기억력, 학습력, 인지력 향상용 조성물 |
| CA3101500A1 (en) * | 2018-06-01 | 2019-12-05 | Laboratory Corporation Of America Holdings | Methods and systems for lc-ms/ms proteomic genotyping |
| JP7124130B2 (ja) * | 2018-06-22 | 2022-08-23 | シナクト ファーマ エーピーエス | 蛋白尿の治療 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005269758B2 (en) * | 2004-07-20 | 2011-11-03 | Genentech, Inc. | Compositions and methods of using angiopoietin-like 4 protein |
| DK2575858T3 (en) * | 2010-06-05 | 2018-03-12 | Sumant S Chugh | METHOD OF TREATING NEPHROTIC SYNDROME AND RELATED DISEASES |
| US9475850B2 (en) * | 2010-06-05 | 2016-10-25 | The Uab Research Foundation | Methods for treatment of nephrotic syndrome and related conditions |
| US20110301103A1 (en) * | 2010-06-05 | 2011-12-08 | Chugh Sumant S | Methods of Treatment |
-
2014
- 2014-03-15 KR KR1020157029360A patent/KR102221041B1/ko active IP Right Grant
- 2014-03-15 WO PCT/US2014/030009 patent/WO2014145275A1/en active Application Filing
- 2014-03-15 NZ NZ712935A patent/NZ712935A/en unknown
- 2014-03-15 CA CA2906982A patent/CA2906982C/en active Active
- 2014-03-15 EP EP14764199.7A patent/EP2970416B1/en active Active
- 2014-03-15 CA CA3207108A patent/CA3207108A1/en active Pending
- 2014-03-15 AU AU2014233219A patent/AU2014233219B2/en active Active
- 2014-03-15 CN CN201480028465.6A patent/CN105229024A/zh active Pending
- 2014-03-15 JP JP2016503307A patent/JP2016516726A/ja active Pending
- 2014-03-15 CA CA3152699A patent/CA3152699C/en active Active
-
2016
- 2016-07-14 HK HK16108291.1A patent/HK1220213A1/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012115277A5 (el) | ||
| JP2011528333A5 (el) | ||
| JP2016516726A5 (el) | ||
| JP2015529685A5 (el) | ||
| JP2015517489A5 (el) | ||
| JP2015078220A5 (el) | ||
| JP2015518818A5 (el) | ||
| WO2012065963A3 (en) | Antiviral condensed heterocyclic compounds | |
| MX2012007410A (es) | Compuestos antivirales novedosos. | |
| JP2012176978A5 (el) | ||
| MX2017004592A (es) | Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos. | |
| JP2012136541A5 (el) | ||
| JP2013520405A5 (el) | ||
| BR112015014457A2 (pt) | composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica e respectivos usos e processos para melhorar ou tratar infecção de hcv, para inibir a atividade da ns5b polimerase do vírus da hepatite c e a replicação de vírus da hepatite c | |
| JP2013136622A5 (el) | ||
| RU2012122162A (ru) | Гликолизированная форма аналога антигенного glp-1 | |
| PE20220938A1 (es) | Compuestos agonistas de gipr | |
| BR112012033715A2 (pt) | inibidores de quinase de regulação de sinal de apoptose. | |
| PH12018500261B1 (en) | Azole benzene derivative | |
| CU20160013A7 (es) | Polipéptidos cíclicos para el tratamiento de la insuficiencia cardíaca | |
| JP2014527040A5 (el) | ||
| JP2011528334A5 (el) | ||
| JP2019520344A5 (el) | ||
| JP2014529399A5 (el) | ||
| JPWO2019156137A5 (el) |